Annette Ekblond
Overview
    Explore the profile of Annette Ekblond including associated specialties, affiliations and a list of published articles.
          
  Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
  
  
  Snapshot
          Snapshot
              Articles
              48
            
            
              Citations
              905
            
            
              Followers
              0
            
  
  Related Specialties
          Related Specialties
  Top 10 Co-Authors
          Top 10 Co-Authors
  Published In
          Published In
  Affiliations
        Affiliations
    Soon will be listed here.
  
  Recent Articles
          1.
        
    
    Qayyum A, Frljak S, Juhl M, Poglajen G, Zemljicl G, Cerar A, et al.
  
  
    ESC Heart Fail
    . 2024 Jul;
          11(6):3882-3891.
    
    PMID: 39039797
  
  
          Aims: Allogeneic stem cell therapy is more logistically suitable compared with autologous cell therapy for large-scale patient treatment. We aim to investigate the clinical safety and efficacy profile of the...
      
2.
        
    
    Hoeeg C, Follin B, Grandjean C, Ripa R, Ekblond A, Kastrup J, et al.
  
  
    Mol Pharm
    . 2024 Jun;
          21(8):3909-3920.
    
    PMID: 38936409
  
  
          Doxorubicin (DOX) is a common and highly effective chemotherapeutic. However, its use is limited by cardiotoxic effects and the lack of methods to detect these at early time points. In...
      
3.
        
    
    Harary Sondergaard R, Hojgaard L, Haack-Sorensen M, Hoeeg C, Monsted Johansen E, Follin B, et al.
  
  
    Stem Cell Res
    . 2024 Apr;
          77:103417.
    
    PMID: 38608355
  
  
          The pro-angiogenic abilities of adipose-derived stromal cells (ASCs) make them attractive candidates for cellular therapy, especially for ischemic disease indications. However, details regarding the underlying mechanisms remain elusive. Therefore, this...
      
4.
        
    
    Jakobsen K, Fenger Carlander A, Todsen T, Melchiors J, Paaske N, Ostergaard Madsen A, et al.
  
  
    Clin Cancer Res
    . 2024 Mar;
          30(10):2078-2084.
    
    PMID: 38441659
  
  
          Purpose: No effective treatment exists for radiation-induced xerostomia. The objective of this study was to compare the effect of adipose-derived mesenchymal stem/stromal cell (ASC) injection, relative to placebo, on salivary...
      
5.
        
    
    Moller-Hansen M, Larsen A, Wiencke A, Terslev L, Siersma V, Andersen T, et al.
  
  
    Ocul Surf
    . 2023 Dec;
          31:1-8.
    
    PMID: 38049032
  
  
          Purpose: This double-blinded randomized clinical trial aimed to evaluate the efficacy of injecting allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland (LG) for the treatment of dry eye...
      
6.
        
    
    Jakobsen K, Fenger Carlander A, Gronhoj C, Todsen T, Melchiors J, Paaske N, et al.
  
  
    Trials
    . 2023 Sep;
          24(1):567.
    
    PMID: 37658468
  
  
          Background: A predominant side effect of radiotherapy for head and neck cancer is salivary gland hypofunction and xerostomia leading to debilitating oral disorders and impaired quality of life (QoL). Intraglandular...
      
7.
        
    
    Follin B, Hoeeg C, Hunter I, Bentsen S, Juhl M, Jensen J, et al.
  
  
    Diagnostics (Basel)
    . 2023 Jan;
          13(2).
    
    PMID: 36673078
  
  
          An increasing number of patients are living with chronic ischemic cardiomyopathy (ICM) and/or heart failure. Treatment options and prognostic tools are lacking for many of these patients. Our aim was...
      
8.
        
    
    Qayyum A, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, et al.
  
  
    Eur J Heart Fail
    . 2023 Jan;
          25(4):576-587.
    
    PMID: 36644821
  
  
          Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac...
      
9.
        
    
    Qayyum A, Mouridsen M, Nilsson B, Gustafsson I, Schou M, Nielsen O, et al.
  
  
    ESC Heart Fail
    . 2023 Jan;
          10(2):1170-1183.
    
    PMID: 36638837
  
  
          Aims: Patients suffering from chronic ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) have reduced quality-of-life, repetitive hospital admissions, and reduced life expectancy. Allogeneic cell therapy is currently...
      
10.
        
    
    Hansen S, Hojgaard L, Kastrup J, Ekblond A, Follin B, Juhl M
  
  
    Front Immunol
    . 2022 Dec;
          13:1085312.
    
    PMID: 36578497
  
  
          The expeditious progress of Mesenchymal Stromal Cells (MSC) for therapeutic intervention calls for means to compare differences in potency of cell products. The differences may be attributed to innumerable sources...